Global drug titan Pfizer has cut its listed severance payouts to executives in the wake of public criticism amid the worldwide economic crisis. Whereas senior management were previously entitled to 2.99 times their annual base pay, plus either their target bonus for the current year, or their actual one for the previous one, under the new scheme, executives will only be eligible for between one and two times their annual pay, plus incentives, in the year of termination.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze